Rapport Therapeutics (RAPP) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Rapport Therapeutics reported total assets of $512.43M and total liabilities of $27.78M. Shareholders' equity was $484.65M, up 58.7% from $305.43M a year earlier. Total debt stood at $11.48M against $490.54M in cash and short-term investments, a net cash position of $479.06M. That puts debt-to-equity at 0.02, compared with 0.00 a year earlier.

Rapport Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Rapport Therapeutics, Inc. (RAPP) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Current Assets
Cash and Cash Equivalents	52.65	56.81	70.17	31.16
Short-Term Investments	437.89	248.48	77.31	0.00
Cash & Short-Term Investments	490.54	305.28	147.48	31.16
Accounts Receivable	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00
Other Current Assets	8.02	4.52	3.39	0.11
Total Current Assets	498.56	309.80	150.87	31.27
Non-Current Assets
Property, Plant & Equipment (Net)	12.89	4.97	4.00	0.34
Other Non-Current Assets	0.99	0.16	0.55	0.00
Total Non-Current Assets	13.87	5.13	4.55	0.34
Total Assets	512.43	314.93	155.42	31.60
Current Liabilities
Accounts Payable	4.19	1.95	2.50	1.45
Short-Term Debt	2.76	0.74	0.67	0.00
Accrued Liabilities	4.98	2.37	5.63	0.21
Other Current Liabilities	12.10	6.08	5.63	0.21
Total Current Liabilities	19.05	8.77	8.80	1.66
Non-Current Liabilities
Long-Term Debt	8.73	0.74	1.48	10.44
Other Non-Current Liabilities	0.00	0.00	170.78	0.00
Total Non-Current Liabilities	8.73	0.74	172.25	10.44
Total Liabilities	27.78	9.51	181.06	12.10
Stockholders' Equity
Common Stock	0.05	0.04	0.00	0.03
Retained Earnings	-235.23	-123.75	-45.44	-10.65
Accumulated Other Comprehensive Income	0.55	-0.52	0.00	0.00
Additional Paid-in Capital	719.29	429.66	19.80	0.56
Shares Outstanding	47.77	36.58	35.38	35.38
Total Stockholders' Equity	484.65	305.43	-25.63	19.51
Total Liabilities & Equity	512.43	314.93	155.42	31.60

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Rapport Therapeutics Balance Sheet

How much debt does Rapport Therapeutics have?

Rapport Therapeutics had total debt of $11.48M as of Dec 31, 2025, against $490.54M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $1.48M a year earlier.

What are Rapport Therapeutics's total assets?

Rapport Therapeutics reported total assets of $512.43M as of Dec 31, 2025, up 62.7% from $314.93M a year earlier. Total liabilities were $27.78M.

What is Rapport Therapeutics's shareholders' equity?

Rapport Therapeutics's shareholders' equity was $484.65M as of Dec 31, 2025, or about $10.15 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition